Insulet | PODD - Operating Expenses


Insulet reported $639.7M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Abbott USD 9.31B 104M Mar/2026
Align Technology USD 862.03M 39.18M Mar/2026
AtriCure USD 140.72M 2.71M Mar/2026
Avanos Medical USD 782.1M 625.97M Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
Becton, Dickinson and Co. USD 24.13B 19.54B Mar/2026
Boston Scientific USD 4.15B 107M Mar/2026
Cardinal Health USD -2.83B 52M Mar/2026
Cooper Companies USD 1.11B 301.2M Mar/2026
Dexcom USD 936.6M 0 Mar/2026
Edwards Lifesciences USD 1.13B 65.4M Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Globus Medical USD 595.85M 49.26M Mar/2026
ICU Medical USD 514.62M 4.48M Dec/2025
Inogen USD 49.14M 665K Sep/2024
Insulet USD 639.7M 2.2M Mar/2026
Integra LifeSciences USD 1.04B 673.49M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Masimo USD 326.2M 2.4M Mar/2026
Medtronic USD 7.72B 436M Mar/2026
Merit Medical Systems USD 337.72M 2.02M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Solventum Corp USD 4.97B 3.08B Mar/2026
Stryker USD 4.92B 284M Mar/2026
Tandem Diabetes Care USD 282.09M 9.97M Dec/2025
Teleflex USD 3.08B 2.55B Mar/2026
West Pharmaceutical Services USD 2.99B 2.35B Mar/2026
Zimmer Biomet Holdings USD 1.69B 249.3M Mar/2026